中文|English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 9
Sep.  2026
Turn off MathJax
Article Contents

Familial type ⅣA hereditary hemochromatosis: A case report

DOI: 10.12449/JCH260922
Research funding:

National Natural Science Foundation of China (82070598);

The Digestive Medical Coordinated Development Center of Beijing Hospitals Authority (XXZ0501);

The Digestive Medical Coordinated Development Center of Beijing Hospitals Authority (XXZ0502)

More Information
  • Corresponding author: Zhang Wei, zhangwei2020@ccmu.edu.cn (ORCID: 0000-0002-9814-2431)
  • Received Date: 2025-12-21
  • Accepted Date: 2026-02-04
  • Published Date: 2026-09-25
  • Hereditary hemochromatosis (HH) is a hereditary disease characterized by iron overload resulting from mutations in genes involved in iron metabolism. Type ⅣA HH, also known as classical ferroportin disease, is caused by loss-of-function mutations in the SLC40A1 gene and has the clinical manifestations of a significant increase in serum ferritin, normal or low transferrin saturation, and marked iron deposition in the spleen. This article reports a case of type ⅣA HH with a significant asymptomatic increase in serum ferritin. Magnetic resonance imaging showed that the severity of iron overload in the spleen was significantly higher than that in the liver; liver biopsy showed mild fatty liver disease and iron deposition in Kupffer cells; gene variation analysis identified a heterozygous mutation in SLC40A1 c.485_487del (p.Val162del). Screening of family members showed that the proband’s mother carried the same variation and had the manifestation of iron overload in the liver and spleen, which further confirmed the pathogenicity of this variation. This case highlights that type ⅣA HH often has an insidious onset and is frequently misdiagnosed. For patients with an unexplained persistent increase in serum ferritin, active genetic testing for HH should be considered, even in the presence of concurrent liver diseases, in order to realize early diagnosis and intervention.

     

  • loading
  • [1]
    Adams P C, Jeffrey G, Ryan J. Haemochromatosis[J]. Lancet, 2023, 401( 10390): 1811- 1821. DOI: 10.1016/S0140-6736(23)00287-8.
    [2]
    Camaschella C, Poggiali E. Rare types of genetic hemochromatosis[J]. Acta Haematol, 2009, 122( 2-3): 140- 145. DOI: 10.1159/000243798.
    [3]
    Kowdley K V, Brown K E, Ahn J, et al. ACG clinical guideline: Hereditary hemochromatosis[J]. Am J Gastroenterol, 2019, 114( 8): 1202- 1218. DOI: 10.14309/ajg.0000000000000315.
    [4]
    Zhang W, Xu A J, Li Y M, et al. A novel SLC40A1 p.Y333H mutation with gain of function of ferroportin: A recurrent cause of haemochromatosis in China[J]. Liver Int, 2019, 39( 6): 1120- 1127. DOI: 10.1111/liv.14013.
    [5]
    Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines for the diagnosis and treatment of hereditary hemochromatosis[J]. Chin J Hepatol, 2024, 32( 9): 787- 798. DOI: 10.3760/cma.j.cn501113-20240712-00319.

    中华医学会肝病学分会. 中国遗传性血色病诊疗指南[J]. 中华肝脏病杂志, 2024, 32( 9): 787- 798. DOI: 10.3760/cma.j.cn501113-20240712-00319.
    [6]
    Hao Kunyan, Wang Yong, Yu Yuecheng. An excerpt of the EASL clinical practice guidelines on haemochromatosis[J]. J Clin Hepatol, 2022, 38( 9): 1999- 2004. DOI: 10.3969/j.issn.1001-5256.2022.09.011.

    郝坤艳, 汪勇, 于乐成.《2022年欧洲肝病学会血色病临床实践指南》摘译[J]. 临床肝胆病杂志, 2022, 38( 9): 1999- 2004. DOI: 10.3969/j.issn.1001-5256.2022.09.011.
    [7]
    Lv T X, Zhang W, Xu A J, et al. Non-HFE mutations in haemochromatosis in China: Combination of heterozygous mutations involving HJV signal peptide variants[J]. J Med Genet, 2018, 55( 10): 650- 660. DOI: 10.1136/jmedgenet-2018-105348.
    [8]
    Mayr R, Janecke A R, Schranz M, et al. Ferroportin disease: A systematic meta-analysis of clinical and molecular findings[J]. J Hepatol, 2010, 53( 5): 941- 949. DOI: 10.1016/j.jhep.2010.05.016.
    [9]
    Zhu Chengyu, Chen Qi, Feng Zhongxin. Hereditary hemochromatosis caused by mutation in the SLC40 A1 gene: A case report[J]. J Clin Hepatol, 2021, 37( 5): 1180- 1182. DOI: 10.3969/j.issn.1001-5256.2021.05.041.

    朱承谕, 陈琦, 封忠昕. SLC40 A1基因突变致遗传性血色病1例报告[J]. 临床肝胆病杂志, 2021, 37( 5): 1180- 1182. DOI: 10.3969/j.issn.1001-5256.2021.05.041.
    [10]
    Girelli D, Busti F, Brissot P, et al. Hemochromatosis classification: Update and recommendations by the BIOIRON Society[J]. Blood, 2022, 139( 20): 3018- 3029. DOI: 10.1182/blood.2021011338.
    [11]
    Uguen K, Ka C, Collod-Béroud G, et al. The spectra of disease-causing mutations in the ferroportin 1(SLC40A1) encoding gene and related iron overload phenotypes(hemochromatosis type 4 and ferroportin disease)[J]. Hum Mutat, 2023, 2023: 5162256. DOI: 10.1155/2023/5162256.
    [12]
    Czaja A J. Review article: Iron disturbances in chronic liver diseases other than haemochromatosis- pathogenic, prognostic, and therapeutic implications[J]. Aliment Pharmacol Ther, 2019, 49( 6): 681- 701. DOI: 10.1111/apt.15173.
    [13]
    Li Guangming, Fan Jiangao. Research progress in role of iron overload in non-alcoholic fatty liver disease[J]. J Clin Hepatol, 2013, 29( 12): 897- 900. DOI: 10.3969/j.issn.1001-5256.2013.12.006.

    李光明, 范建高. 铁超载在非酒精性脂肪性肝病中的作用[J]. 临床肝胆病杂志, 2013, 29( 12): 897- 900. DOI: 10.3969/j.issn.1001-5256.2013.12.006.
    [14]
    Pietrangelo A. Ferroportin disease: Pathogenesis, diagnosis and treatment[J]. Haematologica, 2017, 102( 12): 1972- 1984. DOI: 10.3324/haematol.2017.170720.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)

    Article Metrics

    Article views (88) PDF downloads(15) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return